FDA PCAC reviews 7 peptides in July. Read →

PeptideXpo

CagriSema

Cagrilintide + Semaglutide combination

≥ 99.0% (component-wise for blends)CAS (blend — components have individual CAS numbers)Custom Blends & OEM

Overview

CagriSema is a combination of the long-acting amylin analog Cagrilintide and the GLP-1 agonist Semaglutide, studied in metabolic and weight-management research. Component ratios are configurable; confirm per batch label.

Specifications

CAS
(blend — components have individual CAS numbers)
Purity (HPLC)
≥ 99.0% (component-wise for blends)
Common vial sizes
5 mg, 10 mg, 20 mg
MOQ
On request
Lead time
14–21 days
Storage
-20°C, protect from light

Documentation available on request

  • Certificate of Analysis (COA)
  • HPLC Chromatogram
  • Mass-spec spectrum
  • Stability data
  • SDS / MSDS
  • Sequence verification